ClinicalTrials.gg
WithdrawnNCT05401019OCD-RTUpdated Sep 19, 2024

Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)

A Phase 2 interventional study of Pramipexole and Risperidone in Obsessive-Compulsive Disorder, sponsored by Clinical Academic Center (2CA-Braga). Withdrawn. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Clinical Academic Center (2CA-Braga) · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
This clinical trial was not approved by the regulatory entities. It was reviewed and a new trial was re-submitted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This is a phase 2, randomized, controlled clinical trial to study the efficacy of pramipexol or risperidone in the treatment of refractory ODC patients.

This study is a two-parallel-group clinical trial with duration of 28 weeks (recruitment phase, 4 weeks + treatment phase, 16 weeks + follow-up phase, 8 weeks. The primary endpoint of this study is the score in the Y-BOCS scale measured between baseline and EOT ( at week 16).

02

Conditions studied

  • Obsessive-Compulsive Disorder
03

In context

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Lead sponsor

Clinical Academic Center (2CA-Braga) is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 64 years;
  2. European Portuguese as mother tongue;
  3. Patients diagnosed with OCD, regardless of subtype, according to and/or ICD-10 criteria;
  4. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 16;
  5. Patients who do not respond to treatment with at least two selective serotonin reuptake inhibitor antidepressants (SSRIs) at the maximum tolerated therapeutic dose with or without psychotherapy, i.e. patients in whom there is no reduction in the Y-BOCS score by 25% to 35% relative to the score obtained before starting treatment with SSRIs (Rauch \& Jenike, 1994).

Exclusion criteria

Exclusion Criteria:

  1. Patients who have a complete response to drug treatment with or without psychotherapy, i.e. patients with a reduction in Y-Bocs score by 25% to 35% regarding the score obtained before starting treatment with SSRIS (Rauch \& Jenike, 1994);
  2. Patients with current or anterior history of psychotic illness (schizophrenia, delusions, among others);
  3. Patients with bipolar disorder;
  4. Patients with tick disorder;
  5. Patients with borderline personality disorder;
  6. Patients with social anxiety disorder;
  7. Patients with current or anterior history of dietary behavior disorders (at least in the last 6 months);
  8. patients with a history of neurological disease or traumatic brain injury;
  9. Patients with history of alcohol abuse or illicit substances (at least in the last 6 months);
  10. patients who are passing or have passed in the last 6 months by a major depressive episode;
  11. Patients that undergo deep brain stimulation;
  12. Presence of sensory deficits impeding participation in clinical study;
  13. Pregnant or in breastfeeding period;
  14. Patients doing medication or receiving prohibited treatments;
  15. Patients with to perform MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Experimental arm

    Treatment with pramipexol, once a day, tablet of 0.088, 0.18, 0.35, 0.53 mg per day during 16 weeks

    Drug: Pramipexole

  • Active comparator
    Control arm

    Treatment with Risperidone, once a day, tablet of 0.5, 1, 1.5, 2 mg per day during 16 weeks + 8 weeks follow-up.

    Drug: Risperidone

Interventions

  • Oral medication, once a day during 16 weeks

  • Oral medication, once a day during 16 weeks

06

What researchers measure

Primary outcomes

  1. Y-BOCS total score

    Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score. The Y-BOCS scale measures obsessions separately from compulsions and specifically measures the severity of symptoms of obsessive-compulsive disorder without being biased towards or against the type of content the obsessions or compulsions might present. This instrument consists of 10 self-report items (5 items for obsessions, 5 items for compulsions) that estimate the degree of severity of symptoms (subclinical, mild, moderate, severe or extreme) on a Likert scale ranging from 0 (no symptoms) and 4 (extreme). The final score is calculated as the total sum of all items: subclinical (0 - 7 points), mild (8 - 15 points), moderate (16 - 23 points), severe (24-31) and extreme (32 - 40 points). In the final score, 16 is the cut-off point for symptom severity to be indicative of OCD

    Time frame: Change from Baseline Y-BOCS total score at visit 9 (16 weeks)

Secondary outcomes

  1. Safety outcomes

    Number of adverse events

    Time frame: Change from Baseline at visit 9 (16 weeks)

  2. Biochemical parameters

    Complete blood count, cortisol, adrenocorticotropic hormone, thyroxine and thyroid stimulating hormone values

    Time frame: Change from Baseline at visit 9 (16 weeks)

  3. Neurobiological parameters

    Cortical thickness; functional connectivity of neural networks and static and dynamic connectivity; brain activation during symptom induction; mean diffusivity, fractional anisotropy, axial diffusivity and radial diffusivity

    Time frame: Change from Baseline at visit 9 (16 weeks)

  4. Scores of the 4 subscales of the WHOQOL-bref

    The Quality of Life Scale (WHOQOL-bref) is an instrument that assesses four conceptual domains of quality of life: material and physical well-being, relationships with other people, psychological well-being and environment. This self-report instrument, consisting of a brief sociodemographic questionnaire and 26 statements, quantifies global cognitive judgments of life satisfaction. The final score for each domain is calculated by adding up all the statements corresponding to that domain (D1: Physical - 7 items; D2: Psychological - 6 items; D3: Social Relations - 3 items; D4: Environment - 8 items).

    Time frame: Change from Baseline at visit 9 (16 weeks)

  5. OCI-R Total score

    Obsessive-Compulsive Inventory-Revised (OCI-R) is an self-report instrument that assesses the symptoms of OCD during the last month through 18 statements that are related to everyday situations. The final score is calculated as the total sum of all items, ranging from 0 to 72, with a score greater than 20 indicative of severe symptoms of OCD.

    Time frame: Change from Baseline at visit 9 (16 weeks)

  6. PSS-10 Total score

    Perceived Stress Scale (PSS-10) is a self-report questionnaire to assess perceived stress during the last month. The questionnaire's score is obtained by the sum of the answers in each item, which can vary between 0 and 40 points.

    Time frame: Change from Baseline at visit 9 (16 weeks)

  7. HAM-A Total score

    Hamilton Anxiety Rating Scale (HAM-A) instrument to measure the psychic and somatic components of anxiety. The final score is calculated as the sum total of all items: mild anxiety (0 - 17 points), moderate anxiety (18 - 24 points) and potentially worrying levels of anxiety (25 - 30 points).

    Time frame: Change from Baseline at visit 9 (16 weeks)

  8. HAM-D Total score

    Hamilton Depression Rating Scale (HAM-D) instrument to measure the psychic and somatic components of depression. The final score is calculated as the sum total of all items, from 0 - 7 the participant is considered asymptomatic, while a score equal to or greater than 20 indicates the presence of depressive symptoms. The higher the value, the greater the severity of the symptoms, ranging from moderate to severe.

    Time frame: Change from Baseline at visit 9 (16 weeks)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2022; primary completion for Dec 2026, 54 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
Jun 2, 2022
StartEst.
Jun 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05401019
Lead sponsor
Clinical Academic Center (2CA-Braga)
Collaborators
University of Minho
Responsible party
Sponsor
First posted
Jun 2, 2022
Start date
Jun 2022 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion